Current topics tracker
Heart and Metabolic Health
Tracks the weight-loss, cholesterol, blood sugar, and blood-pressure issues people search when they want fast cardiometabolic fixes.
Active
4 tracked concerns
40 recent PubMed papers
Updated March 27, 2026 at 9:01 AM
How to read this page
This is a fast-moving signal tracker, not a diagnosis page
These tracker pages blend recent EasyNIH search interest, NIH news-release matches, and recent PubMed publication activity. They refresh about once a day.
Table of contents
Jump to a tracked concern
Drugs
GLP-1 weight-loss drugs
Active
This is still one of the biggest health-search topics online, especially around dosing, side effects, muscle loss, compounding, and what happens after stopping.
EasyNIH matches
NIH news hits
39 PubMed papers
39 recent PubMed papers matched this topic.
lean mass loss
compounded products
microdosing claims
coming off treatment
DrugsWeight loss
Devices
CGMs for people without diabetes
Watch list
Continuous glucose monitors are being sold as performance and longevity tools even for people who are mainly curious, not diabetic.
EasyNIH matches
NIH news hits
1 PubMed papers
1 recent PubMed paper matched this topic.
data overload
normal glucose swings being treated like disease
food fear created by constant monitoring
DevicesMetabolic
Diagnostics
ApoB, LDL particle, and advanced lipid testing
Watch list
More people want deeper cholesterol tracking and keep asking whether ApoB tells them more than a standard lipid panel.
EasyNIH matches
NIH news hits
PubMed papers
This is still on the watch list, but the last daily refresh did not find a strong signal yet.
over-testing without a treatment plan
statin hesitancy
social-media lipid optimization claims
DiagnosticsHeart
Supplements
Electrolyte and hydration hype
Watch list
Electrolyte mixes keep getting framed like a universal performance or energy fix, even when the person is not losing much sodium in the first place.
EasyNIH matches
NIH news hits
PubMed papers
This is still on the watch list, but the last daily refresh did not find a strong signal yet.
high-sodium products
hydration marketing for sedentary people
blood-pressure considerations
SupplementsPerformance
Editorial spotlights
Topics on this page that already have stronger source notes
Compounded GLP-1s
Online weight-loss demand keeps blurring FDA-approved GLP-1s and compounded versions into one bucket even though the risk profile is not identical.
People are asking about cost, muscle loss, compounding safety, and what happens after stopping.
Bottom line: GLP-1 drugs can work well, but compounded products and body-composition tradeoffs need their own separate conversation.
Zone 2 training
Zone 2 remains popular because it sounds precise and scientific, but it is often treated as more universally optimal than the evidence supports.
Longevity and performance media keep tying it to mitochondrial health and better aging.
Bottom line: Low-intensity aerobic work matters, but it should not crowd out strength or harder conditioning for most people.